Risk factors for acute kidney injury at presentation among children with CNS malaria: a case control study.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
01 Nov 2022
Historique:
received: 03 05 2022
accepted: 18 10 2022
entrez: 1 11 2022
pubmed: 2 11 2022
medline: 3 11 2022
Statut: epublish

Résumé

Recent research has established that acute kidney injury (AKI) is a common problem in severe paediatric malaria. Limited access to kidney diagnostic studies in the low resources settings where malaria is common has constrained research on this important problem. Enrolment data from an ongoing clinical trial of antipyretics in children with central nervous system (CNS) malaria, CNS malaria being malaria with seizures or coma, was used to identify risk factors for AKI at presentation. Children 2-11 years old with CNS malaria underwent screening and enrollment assessments which included demographic and anthropomorphic data, clinical details regarding the acute illness, and laboratory studies including creatinine (Cr), quantitative parasite count (qPC), quantitative histidine rich protein 2 (HRP2), lactate, and bilirubin levels. Children with a screening Cr > 106 µmol/l were excluded from the study due to the potential nephrotoxic effects of the study drug. To identify risk factors for AKI at the time of admission, children who were enrolled in the study were categorized as having AKI using estimates of their baseline (i.e. before this acute illness) kidney function and creatinine at enrollment applying the Kidney Disease: Improving Global Outcome (KDIGO) 2012 guidelines. Logistic regressions and a multivariate model were used to identify clinical and demographic risk factors for AKI at presentation among those children enrolled in the study. 465 children were screened, 377 were age-appropriate with CNS malaria, 22 (5.8%) were excluded due to Cr > 106 µmol/l, and 209 were enrolled. Among the 209, AKI using KDIGO criteria was observed in 134 (64.1%). One child required dialysis during recovery. Risk factors for AKI in both the logistic regression and multivariate models included: hyperpyrexia (OR 3.36; 95% CI 1.39-8.12) and age with older children being less likely to have AKI (OR 0.72; 95% CI 0.62-0.84). AKI is extremely common among children presenting with CNS malaria. Hyperpyrexia with associated dehydration may contribute to the AKI or may simply be a marker for a more inflammatory systemic response that is also affecting the kidney. Appropriate fluid management in children with CNS malaria and AKI may be challenging since generous hydration to support kidney recovery could worsen malaria-induced cerebral oedema in this critically ill population. Trial registration https://clinicaltrials.gov/ct2/show/NCT03399318.

Sections du résumé

BACKGROUND BACKGROUND
Recent research has established that acute kidney injury (AKI) is a common problem in severe paediatric malaria. Limited access to kidney diagnostic studies in the low resources settings where malaria is common has constrained research on this important problem.
METHODS METHODS
Enrolment data from an ongoing clinical trial of antipyretics in children with central nervous system (CNS) malaria, CNS malaria being malaria with seizures or coma, was used to identify risk factors for AKI at presentation. Children 2-11 years old with CNS malaria underwent screening and enrollment assessments which included demographic and anthropomorphic data, clinical details regarding the acute illness, and laboratory studies including creatinine (Cr), quantitative parasite count (qPC), quantitative histidine rich protein 2 (HRP2), lactate, and bilirubin levels. Children with a screening Cr > 106 µmol/l were excluded from the study due to the potential nephrotoxic effects of the study drug. To identify risk factors for AKI at the time of admission, children who were enrolled in the study were categorized as having AKI using estimates of their baseline (i.e. before this acute illness) kidney function and creatinine at enrollment applying the Kidney Disease: Improving Global Outcome (KDIGO) 2012 guidelines. Logistic regressions and a multivariate model were used to identify clinical and demographic risk factors for AKI at presentation among those children enrolled in the study.
RESULTS RESULTS
465 children were screened, 377 were age-appropriate with CNS malaria, 22 (5.8%) were excluded due to Cr > 106 µmol/l, and 209 were enrolled. Among the 209, AKI using KDIGO criteria was observed in 134 (64.1%). One child required dialysis during recovery. Risk factors for AKI in both the logistic regression and multivariate models included: hyperpyrexia (OR 3.36; 95% CI 1.39-8.12) and age with older children being less likely to have AKI (OR 0.72; 95% CI 0.62-0.84).
CONCLUSION CONCLUSIONS
AKI is extremely common among children presenting with CNS malaria. Hyperpyrexia with associated dehydration may contribute to the AKI or may simply be a marker for a more inflammatory systemic response that is also affecting the kidney. Appropriate fluid management in children with CNS malaria and AKI may be challenging since generous hydration to support kidney recovery could worsen malaria-induced cerebral oedema in this critically ill population. Trial registration https://clinicaltrials.gov/ct2/show/NCT03399318.

Identifiants

pubmed: 36316704
doi: 10.1186/s12936-022-04327-y
pii: 10.1186/s12936-022-04327-y
pmc: PMC9624036
doi:

Substances chimiques

Creatinine AYI8EX34EU

Banques de données

ClinicalTrials.gov
['NCT03399318']

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

310

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS102176
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS111057
Pays : United States
Organisme : NIH HHS
ID : R35NS122265
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS122265
Pays : United States
Organisme : NIH HHS
ID : R01NS102176
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Infect Immun. 2004 Oct;72(10):5630-7
pubmed: 15385460
Trop Doct. 2012 Oct;42(4):203-5
pubmed: 22869838
BMC Infect Dis. 2017 Apr 27;17(1):313
pubmed: 28449641
Clin Biochem. 2010 Aug;43(12):1026-9
pubmed: 20416292
Clin Infect Dis. 2003 Nov 15;37(10):1340-8
pubmed: 14583868
Am J Trop Med Hyg. 2010 Feb;82(2):231-4
pubmed: 20133998
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
Kidney Int Rep. 2020 Apr 19;5(7):991-999
pubmed: 32647756
BMC Med. 2019 May 21;17(1):98
pubmed: 31109328
Trop Med Int Health. 2014 Sep;19 Suppl 1:7-131
pubmed: 25214480
Front Cell Infect Microbiol. 2017 Jul 20;7:324
pubmed: 28775960
Malar J. 2006 Oct 10;5:85
pubmed: 17029647
Trop Parasitol. 2014 Jul;4(2):105-10
pubmed: 25250231
Malar J. 2014 Mar 12;13:91
pubmed: 24618154
Clin Biochem. 2017 Mar;50(4-5):238-240
pubmed: 27863965
Trop Med Int Health. 2007 Sep;12(9):1037-50
pubmed: 17875015
J Crit Care. 2018 Feb;43:356-360
pubmed: 29132978
Trans R Soc Trop Med Hyg. 2009 Jul;103(7):665-71
pubmed: 19344925
N Engl J Med. 2015 Mar 19;372(12):1126-37
pubmed: 25785970
BMC Nephrol. 2020 Sep 29;21(1):417
pubmed: 32993548
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Lancet Neurol. 2010 Dec;9(12):1173-1181
pubmed: 21056005
EClinicalMedicine. 2022 Feb 12;44:101292
pubmed: 35198918
Q J Med. 1989 May;71(265):441-59
pubmed: 2690177
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11825-9
pubmed: 12177447
J Infect Dis. 2012 Aug 1;206(3):309-18
pubmed: 22634877
PLoS One. 2018 May 1;13(5):e0196586
pubmed: 29715307
Curr Opin Infect Dis. 2018 Feb;31(1):69-77
pubmed: 29206655
West J Emerg Med. 2013 Feb;14(1):58-62
pubmed: 23451290
Open Forum Infect Dis. 2016 Feb 26;3(2):ofw046
pubmed: 27186577
JAMA. 2005 Mar 23;293(12):1461-70
pubmed: 15784869
Int J Nephrol Renovasc Dis. 2021 Jul 08;14:235-253
pubmed: 34267538
Front Immunol. 2021 Apr 23;12:651739
pubmed: 33968051

Auteurs

Derby Tembo (D)

Department of Paediatrics and Child Health, Chipata Central Hospital, Chipata, Zambia.

Suzanna Mwanza (S)

Department of Paediatrics and Child Health, Chipata Central Hospital, Chipata, Zambia.

Chisambo Mwaba (C)

Dept. of Paediatric & Child Health, University of Zambia School of Medicine, Lusaka, Zambia.

Ifunanya Dallah (I)

Department of Neurology, University of Rochester, Rochester, NY, 14642, USA.

Somwe Wa Somwe (S)

University Teaching Hospitals, Neurology Research Office, Lusaka, Zambia.

Karl B Seydel (KB)

Blantyre Malaria Project, Kamuzu University of Health Sciences, Blantyre, Malawi.
Dept. of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA.

Gretchen L Birbeck (GL)

Dept. of Paediatric & Child Health, University of Zambia School of Medicine, Lusaka, Zambia. gretchen_birbeck@urmc.rochester.edu.
Department of Neurology, University of Rochester, Rochester, NY, 14642, USA. gretchen_birbeck@urmc.rochester.edu.
University Teaching Hospitals Children's Hospital, Lusaka, Zambia. gretchen_birbeck@urmc.rochester.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH